Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

CompletedOBSERVATIONAL
Enrollment

479

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

February 28, 2018

Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
DRUG

Rebif

DRUG

Tecfidera

Trial Locations (23)

11042

Neurological Associates of Long Island, Lake Success

14203

University of Buffalo Clinical and Translational research Center, Buffalo

24073

Blacksburg Neurology, Christiansburg

27607

Raleigh Neurology Associates, Raleigh

28277

Onsite Clinical Solutions, Charlotte

31406

Savannah Neurology Specialists, Savannah

35209

Alabama Neurology Associates, Birmingham

44685

Oak Clinic-Multiple Sclerosis, Uniontown

45459

Dayton Center for Neurological Disorders, Centerville

54956

Neuroscience Group, Neenah

55422

Minneapolis Clinic of Neurology, Golden Valley

60201

Northshore University, Evanston

61637

OSF Multi-specialty Group d/b/a Illinois Neurological Institute, Peoria

63110

Washington university, St Louis

68588

University of Nebraska Medical Center, Lincoln

78229

The university of Texas Health Science Center at San Antonio, San Antonio

80907

Colorado Springs Neurological Associates, Colorado Springs

97228

Providence St. Vincent Medical Center, Portland

98405

MultiCare Health System, Tacoma

02135

St Elizabeths/ Dragonfly Research, Brighton

01805

Lahey Clinic, Burlington

05405

University of Vermont, Burlington

H2X 0A9

Centre Hospitalier de l'Universite de Montreal, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

EMD Serono

INDUSTRY

lead

IMS HEALTH GmbH & Co. OHG

INDUSTRY

NCT02823951 - Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® | Biotech Hunter | Biotech Hunter